Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. E. (Edwin) Bremer

Publicaties

Atezolizumab Consolidation in Patients with High Risk Diffuse Large B-cell Lymphoma in Complete Remission after R-CHOP

Antibody desolvation with sodium chloride and acetonitrile generates bioactive protein nanoparticles

Design of Vaterite Nanoparticles for Controlled Delivery of Active Immunotherapeutic Proteins

Direct Functionalization of Polysaccharide-Based Xylan Phenyl Carbonate Nanoparticles with Tumor Cell Specific Antibodies

Novel high-yield potato protease inhibitor panels block a wide array of proteases involved in viral infection and crucial tissue damage

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

A luminescence-based method to assess antigen presentation and antigen-specific T cell responses for in vitro screening of immunomodulatory checkpoints and therapeutics

Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit

EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells

Pers/media

Groningse CAR-T-celtherapie krijgt KWF-subsidie

2,6 miljoen subsidie voor revolutionair oncologie onderzoek

UMCG ontvangt grote EU-subsidie voor onderzoek naar nieuwe immuuntherapie bij kanker

Grote EU-subsidie voor UMCG voor onderzoek naar CAR-T immuuntherapie bij kanker

Nationaal Groeifonds investeert in UMCG-studies om ontwikkeling kankermedicijnen te versnellen

PR Newswire Global Biotech

Ruim 5 miljoen voor uniek Nederlands platform voor gen- en celtherapie

Ruim 5 miljoen voor cel- en gentherapie